D., Joly, E., Horsmans, Y., & Delzenne, N
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, may induce a specific microbial footprint that differs from pure GLP-1 agonism, as GIP signaling independently participates in lipid handling and mucosal immune regulation, potentially modifying the nutrient-delivery profile to the gut ( Overall, differences between studies likely reflect heterogeneity in patient populations, diet, baseline microbiota, and treatment duration
References The following publications are provided for general scientific background regarding GLP-1 receptor agonist research
UCP1 is a proton channel which allows dissipation of the proton gradient across the mitochondrial matrix, without adenosine triphosphate (ATP) production
Prescription History: Proof that the patient was prescribed and took the GLP-1 medication (Ozempic, Mounjaro, etc.) before the severe symptoms began